Download ALL Selected Citations to Citation Manager

Selected Abstracts

Returned: 1 citations and abstracts. Click on down arrow or scroll to see abstracts.

Ugo De Giorgi, Vicente Valero, Eric Rohren, Shaheenah Dawood, Naoto T. Ueno, M. Craig Miller, Gerald V. Doyle, Summer Jackson, Eleni Andreopoulou, Beverly C. Handy, James M. Reuben, Herbert A. Fritsche, Homer A. Macapinlac, Gabriel N. Hortobagyi, and Massimo Cristofanilli

Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer
J. Clin. Oncol. 27: 3303-3311.

Abstract 1 of 1

Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer

From The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Immunicon Corp, Huntingdon Valley, PA.

Corresponding author: Massimo Cristofanilli, MD, FACP, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030; e-mail: mcristof{at}mdanderson.org.

Purpose Circulating tumor cells (CTCs) and [¹⁸F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) are two new promising tools for therapeutic monitoring. In this study, we compared the prognostic value of CTC and FDG-PET/CT monitoring during systemic therapy for metastatic breast cancer (MBC).

Patients and Methods A retrospective analyses of 115 MBC patients who started a new line of therapy and who had CTC counts and FDG-PET/CT scans performed at baseline and at 9 to 12 weeks during therapy (midtherapy) was performed. Patients were categorized according to midtherapy CTC counts as favorable (ie, < five CTCs/7.5 mL blood) or unfavorable ( five CTCs/7.5 mL blood) outcomes. CTC counts and FDG-PET/CT response at midtherapy were compared, and univariate and multivariate analyses were performed to identify factors associated with survival.

Results In 102 evaluable patients, the median overall survival time was 14 months (range, 1 to > 41 months). Midtherapy CTC levels correlated with FDG-PET/CT response in 68 (67%) of 102 evaluable patients. In univariate analysis, midtherapy CTC counts and FDG-PET/CT response predicted overall survival (P < .001 and P = .001, respectively). FDG-PET/CT predicted overall survival (P = .0086) in 31 (91%) of 34 discordant patients who had fewer than five CTCs at midtherapy. Only midtherapy CTC levels remained significant in a multivariate analysis (P = .004).

Conclusion Detection of five or more CTCs during therapeutic monitoring can accurately predict prognosis in MBC beyond metabolic response. FDG-PET/CT deserves a role in patients who have fewer than five CTCs at midtherapy. Prospective trials should evaluate the most sensitive and cost-effective modality for therapeutic monitoring in MBC.

Supported by a grant from A. Serra Association, Lecce, Italy.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

[ Full Text of De Giorgi et al.] [Reprint (PDF) Version of De Giorgi et al.]